Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Boxenbaum

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Regulatory Toxicology and Pharmacology : RTP|February 19, 2014
Vertical allometry: fact or fiction?Iftekhar Mahmood, Harold Boxenbaum
Clinical Pharmacology and Therapeutics|October 31, 2003
The bioavailability of intranasal and smoked methamphetamineDebra S Harris, Harold Boxenbaum, E Thomas Everhart, et al.
Anti-Cancer Drugs|March 14, 2003
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerChristine E Swenson, Lois E Bolcsak, Gerald Batist, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Regulatory Toxicology and Pharmacology : RTP|February 19, 2014
Vertical allometry: fact or fiction?Iftekhar Mahmood, Harold Boxenbaum
Clinical Pharmacology and Therapeutics|October 31, 2003
The bioavailability of intranasal and smoked methamphetamineDebra S Harris, Harold Boxenbaum, E Thomas Everhart, et al.
Anti-Cancer Drugs|March 14, 2003
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerChristine E Swenson, Lois E Bolcsak, Gerald Batist, et al.
Pageof 1